|

Clonal Hematopoiesis Chemotherapy and Radiation Effects Study

RECRUITINGSponsored by Dana-Farber Cancer Institute
Actively Recruiting
SponsorDana-Farber Cancer Institute
Started2025-04-04
Est. completion2028-06-30
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site

Summary

The goal of the Clonal Hematopoiesis Chemotherapy and Radiation Effects (CH CARE) Study is to understand how the presence or absence of clonal hematopoiesis (CH) influences outcomes in people receiving chemotherapy and radiation for solid cancers. The study will collect biospecimens and clinical information. These data will be used to define clinical and molecular features that predict the presence of high-risk clonal hematopoiesis (CH) in patients exposed to cytotoxic anti-cancer therapy. Predictive features will be utilized to identify populations of cancer patients and survivors who are at the highest risk of developing therapy-related myeloid neoplasms (t-MNs). Ultimately this study will result in the development of a novel novel risk prediction algorithm for t-MNs in patients with solid cancers and drive potential therapeutic approaches to intercept progression from CH to often fatal t-MNs.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Participants to be included in this study include the following:
* Adults age \>18 years
* Diagnosed with solid malignancy (breast, ovarian, lung, gastric, colorectal, esophageal, uterine, head and neck, or sarcoma cancers)
* Have a pending plan to receive chemotherapy or radiation for their solid malignancy (cancer).
* Has not received cytotoxic chemotherapy or radiation for their solid cancer diagnosis in the past.

Exclusion Criteria:

* Individuals without plans for cytotoxic chemotherapy, radiation or PARP inhibitor exposure
* Individuals who have received prior chemotherapy and or radiation for their current solid malignancy (cancer)
* Individuals with any prior history of blood cancer (leukemia, myelodysplastic syndrome, lymphoma, multiple myeloma, including smoldering multiple myeloma). Persons with blood cancer precursors including clonal hematopoiesis of indeterminate potential (CHIP), clonal cytopenia of uncertain significance (CCUS), monoclonal B lymphocytosis (MBL), monoclonal gammopathy of uncertain significance (MGUS) are eligible for study participation.

Conditions19

Breast CancerCancerClonal Cytopenia of Undetermined SignificanceClonal Hematopoiesis of Indeterminate Potential (CHIP)Colorectal (Colon or Rectal) CancerEndometrial AdenocarcinomaEsophageal AdenocarcinomaGastric (Stomach) CancerHead and Neck CancerLung Cancer

Locations1 site

Dana-Farber Cancer Institute

Find trials near these locations

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.